SANOFI-AVENTIS (EPA:SAN) Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Transparency directive : regulatory news
17/04/2024 07:00
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
30/04/2024 22:32
30/04/2024 22:00
30/04/2024 20:36
30/04/2024 18:16
30/04/2024 19:35
30/04/2024 07:36
30/04/2024 20:56
30/04/2024 16:01
30/04/2024 15:42
30/04/2024 20:44
30/04/2024 18:10
30/04/2024 20:22
30/04/2024 16:44
30/04/2024 18:57
30/04/2024 21:28
30/04/2024 20:33
30/04/2024 19:33
30/04/2024 19:12
30/04/2024 17:14
30/04/2024 18:17
30/04/2024 19:47
30/04/2024 16:00
30/04/2024 17:33
30/04/2024 20:34
30/04/2024 21:25
30/04/2024 17:45
30/04/2024 22:53
30/04/2024 19:57
30/04/2024 21:09
30/04/2024 20:17
30/04/2024 11:43
29/04/2024 12:00
30/04/2024 17:42
29/04/2024 19:33
30/04/2024 10:49
30/04/2024 16:41
30/04/2024 14:27
30/04/2024 12:32